Atopic Dermatitis Drugs Market (Drug Class: Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants, Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2030

Exponential Growth of Biologic Drugs Favor Market Growth

According to a study published by BioMed Central, U.K - an electronic-only medical journal, it was found that, on a global level, ~15 - 20% children and ~1 - 3% adults suffer from atopic dermatitis (AD). The growing prevalence of this disease has triggered the demand for efficacious drugs in the atopic dermatitis drugs market.

Biologic drugs are projected for exponential growth during the forecast period. In 2018, biologic drugs accounted for the highest market share of ~42%, and continue to dominate the market share with a projected value of ~77% in 2027. Thus, it is evident that, healthcare companies in the atopic dermatitis drugs market are increasing research & development activities to improve the efficacy of biologic drugs in order to provide instant relief for patients.

Since atopic dermatitis has a high risk of recurrence, healthcare companies in the atopic dermatitis drugs market are identifying drugs that improve the functioning of the immune system by helping to fight off bacteria and viruses. For instance, in August 2019, Sanofi - a French multinational pharmaceutical company, announced the approval of Dupixent® (dupilumab) - a biologic drug to treat moderate-to-severe atopic dermatitis, by the European Commission.

Topical PDE4 Inhibitor Drugs Emerge as Non-steroid-based Option

Healthcare companies in the atopic dermatitis drugs market are developing new drug agents to expand the treatment options for the disease. They are developing new moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs. Manufacturers are making these treatment options available at retail and hospital pharmacies.

After several clinical trials, healthcare companies are introducing efficacious ointments that provide result-oriented outcome in patients. In 2027, PDE4 inhibitor (Phosphodiesterase Type 4 inhibitor) drugs will hold the second-highest revenue after biologic drugs in the atopic dermatitis drugs market. On that account, healthcare companies are propelling the use of nonsteroidal topical ointments that prevent the release of cyclic adenosine monophosphate (cAMP), which is one of the major causes that aggravates atopic dermatitis.

Get a glimpse of the in-depth analysis through our Report Brochure

Stakeholders in the atopic dermatitis drugs market are gaining the faith of patients, as nonsteroidal topical ointments are considered safer and better than topical corticosteroids, especially for younger patients. Due to the high prevalence of atopic dermatitis in children, healthcare providers in the atopic dermatitis drugs landscape are observing a shift in consumer preference, as caregivers are hesitant to opt for steroid-based options.

Experimental Biologics Reduce Side Effects of Atopic Dermatitis Drugs

Although topical treatment drugs are projected for growth in the atopic dermatitis drugs market, in many cases, these treatments have been ineffective in many patients. As a result, patients are advised to opt for traditional immunosuppressant medications such as cyclosporin (CYA) and methotrexate (MTX). These immunosuppressants show effectiveness in AD, but their routine use is demonstrated with incompetent disease responses and other adverse effects in patients. Also, there is a risk of renal, hepatic, and other toxicities in body organs that adversely affect the healing period of these treatment options.

Thereupon, healthcare companies are approaching experimental biologics to prevent the toxicity and improve the efficacy of atopic dermatitis drugs. They should focus on preventing skin inflammation and flares while minimizing the side effects of these drugs.

Analysts’ Viewpoint on Atopic Dermatitis Drugs Market

Although the trend of online pharmacies is gaining momentum in the atopic dermatitis drugs market, caregivers and patients have more faith in retail pharmacies. This is expected to manifest during the forecast period, as the retail pharmacies sector will grow from ~US$ 1.3 billion in 2018 to ~US$ 15.3 billion by 2027. However, the side effects of certain classes of atopic dermatitis drugs is one of the major challenges for stakeholders in the supply chain. On that account, market players should opt for a multidimensional approach, and educate parents and healthcare providers regarding the availability of pharmacological therapies. Also, healthcare companies should develop new drug agents in biologics that gain FDA (Food and Drug Administration) approval.

Atopic Dermatitis Drugs Market: Overview

The global atopic dermatitis drugs market for the historical period of 2017 and forecast period of 2019 to 2027, rise in investments toward research & development and novel pipeline drugs are projected to boost the growth of the global atopic dermatitis drugs market during the forecast period.

The global atopic dermatitis drugs market generated ~US$ 2.2 Bn in revenue in 2018, and is expected to expand at a CAGR of ~27% during the forecast period.

Novel Pipeline Drugs and Rise in Incidence Rate of Atopic Dermatitis: Key Drivers

Dermatological disorders differ across the globe, based on geographic location, climatic conditions, socioeconomic status, lifestyles, age, gender, heredity, and personal habits.

According to the World Health Organization (WHO), over 900 million people were affected with skin diseases in 2017, and five common skin disorders, which include atopic dermatitis, accounted for around 80% of the skin disorders.

The high prevalence and substantial rise in incidence rate of atopic dermatitis across the globe is the key factor driving the atopic dermatitis drugs market. Atopic dermatitis, a common and chronic inflammatory skin disease, affects 15% to 20% children and 1% to 3% adults across the world, every year.

Leading pharmaceutical companies strive to address these unmet medical needs through new product developments.

AbbVie Inc. is planning to launch Upadacitinib, which is a JAK inhibitor, by 2021, for the treatment of atopic dermatitis. Currently, phase 2 clinical data in atopic dermatitis supports advancement toward phase 3.

New approvals and commercialization of novel therapeutic drugs under clinical trial studies are projected to drive the global atopic dermatitis drug market during the forecast period.

Biologics Drug Class Leads Market

The biologics segment dominated the global atopic dermatitis drugs market in 2018, and is expected to account for a major market share during the forecast period, owing to an increase in the preference of patients for biologics, since they are effective. Anticipated launches and adoption of biologic drugs between 2019 and 2022 is a key trend that is expected to propel the biologics segment during the forecast period.

The PDE4 inhibitors segment in the global atopic dermatitis drugs market is projected to expand at significant CAGR during the forecast period. Rise in the prevalence of eczema is a driving factor that is expected to propel the segment during the forecast period.

Atopic dermatitis is one of the most common types of eczema. It is a chronic, inflammatory skin disorder, with a prevalence as high as 20% in children and 1% to 3% in adults.

North America to Dominate Global Atopic Dermatitis Drugs Market

North America accounted for a major share of the global atopic dermatitis drugs market in 2018, followed by Europe. Early adoption of biologics, favorable healthcare reimbursement policies in the U.S. and Canada, and rapid increase in market penetration of new players with novel therapeutic drugs are likely to drive the atopic dermatitis drugs market in North America.

Europe was also an attractive market for atopic dermatitis drugs in 2018. Economic revival in the European Union has resulted in enhanced healthcare expenditure, and hence, increased adoption of biologics and PD34 inhibitors in the healthcare industry in the region is likely to drive the market. Further, well-established healthcare facilities, new product approvals, and commercialization and favorable medical reimbursement policies are anticipated to drive the market in the region.

The atopic dermatitis drugs market in Asia Pacific is estimated to grow at a faster pace than other regions during the forecast period, due to increase in the focus on the development of healthcare infrastructure by public as well as private hospitals, along with rise in the demand for novel therapeutics among a significant patient population. Additionally, wide scope of development and rapid urbanization offer significant opportunities to emerging as well as established players in the region. This, in turn, drives the market in Asia Pacific.

Global Atopic Dermatitis Drugs Market: Competitive Landscape

Detailed profiles of the manufacturers of atopic dermatitis drugs have been provided in the report to evaluate their key product offerings, financials, business strategies, and recent developments.

Key players operating in the global atopic dermatitis drugs market include

• Mylan N.V.
• Pfizer, Inc.
• LEO Pharma A/S
• Sanofi
• Novartis AG
• Bausch Health
• Teva Pharmaceutical Industries Ltd.

Key Questions Answered in TMR’s Atopic Dermatitis Drugs Market Study

• What is the scope of growth of atopic dermatitis drug companies in the pharmaceutical drugs sector?
• What is the estimated Y-o-Y growth of the market from 2019 to 2027?
• What is the influence of the changing trends in technologies on the  market?
• Is North America likely to continue to remain the most profitable regional market for atopic dermatitis drug providers?
• Which factors are expected to hamper the market during the forecast period?
• Which are the leading companies in the global market?

Segmentation of the Atopic Dermatitis Drugs Market

Drug Class

• Corticosteroids
• PDE4 Inhibitors
• Biologics
• Skin Barrier Emollients
• CNI Immunosuppressants
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Atopic Dermatitis Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, 2017–2027

5. Market Outlook

    5.1. Disease Epidemiology 

    5.2. Pipeline Analysis

    5.3. Recent Development 

6. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Drug Class

    6.1. Introduction & Definition

    6.2. Market Value Forecast by Drug Class, 2017–2027

        6.2.1. Corticosteroids 

        6.2.2. PDE4 Inhibitors

        6.2.3. Biologics 

        6.2.4. Skin Barrier Emollients 

        6.2.5. CNI Immunosuppressants

        6.2.6. Others 

    6.3. Market Attractiveness by Drug Class

7. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Distribution Channel 

    7.1. Introduction & Definition

    7.2. Market Value Forecast by Distribution Channel, 2017–2027

        7.2.1. Hospital Pharmacies

        7.2.2. Retail Pharmacies 

        7.2.3. Online Pharmacies 

    7.3. Market Attractiveness by Distribution Channel 

8. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Region

    8.1. Key Findings

    8.2. Market Value Forecast by Region

        8.2.1. North America 

        8.2.2. Europe 

        8.2.3. Asia Pacific 

        8.2.4. Latin America 

        8.2.5. Middle East & Africa 

    8.3. Market Attractiveness by Country/Region

9. North America Atopic Dermatitis Drugs Market Analysis and Forecast

    9.1. Introduction

    9.2. Market Value Forecast by Drug Class, 2017–2027

        9.2.1. Corticosteroids 

        9.2.2. PDE4 Inhibitors

        9.2.3. Biologics 

        9.2.4. Skin Barrier Emollients 

        9.2.5. CNI Immunosuppressants

        9.2.6. Others 

    9.3. Market Value Forecast by Distribution Channel, 2017–2027

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies 

        9.3.3. Online Pharmacies 

    9.4. Market Value Forecast by Country, 2017–2027

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis 

        9.5.1. By Drug Class

        9.5.2. By Distribution Channel 

        9.5.3. By Country

10. Europe Atopic Dermatitis Drugs Market Analysis and Forecast

    10.1. Introduction

    10.2. Market Value Forecast by Drug Class, 2017–2027

        10.2.1. Corticosteroids 

        10.2.2. PDE4 Inhibitors

        10.2.3. Biologics 

        10.2.4. Skin Barrier Emollients 

        10.2.5. CNI Immunosuppressants

        10.2.6. Others 

    10.3. Market Value Forecast by Distribution Channel, 2017–2027

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies 

        10.3.3. Online Pharmacies 

    10.4. Market Value Forecast by Country/Sub-region, 2017–2027

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis 

        10.5.1. By Drug Class

        10.5.2. By Distribution Channel 

        10.5.3. By Country/Sub-region

11. Asia Pacific Atopic Dermatitis Drugs Market Analysis and Forecast

    11.1. Introduction

    11.2. Market Value Forecast by Drug Class, 2017–2027

        11.2.1. Corticosteroids 

        11.2.2. PDE4 Inhibitors

        11.2.3. Biologics 

        11.2.4. Skin Barrier Emollients 

        11.2.5. CNI Immunosuppressants

        11.2.6. Others 

    11.3. Market Value Forecast by Distribution Channel, 2017–2027

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies 

        11.3.3. Online Pharmacies 

    11.4. Market Value Forecast by Country/Sub-region, 2017–2027

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis 

        11.5.1. By Drug Class

        11.5.2. By Distribution Channel 

        11.5.3. By Country/Sub-region

12. Latin America Atopic Dermatitis Drugs Market Analysis and Forecast

    12.1. Introduction

    12.2. Market Value Forecast by Drug Class, 2017–2027

        12.2.1. Corticosteroids 

        12.2.2. PDE4 Inhibitors

        12.2.3. Biologics 

        12.2.4. Skin Barrier Emollients 

        12.2.5. CNI Immunosuppressants

        12.2.6. Others 

    12.3. Market Value Forecast by Distribution Channel, 2017–2027

        12.3.1. Hospital Pharmacies

        12.3.2. Retail Pharmacies 

        12.3.3. Online Pharmacies 

    12.4. Market Value Forecast by Country/Sub-region, 2017–2027

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis 

        12.5.1. By Drug Class

        12.5.2. By Distribution Channel 

        12.5.3. By Country/Sub-region

13. Middle East & Africa Atopic Dermatitis Drugs Market Analysis and Forecast

    13.1. Introduction

    13.2. Market Value Forecast by Drug Class, 2017–2027

        13.2.1. Corticosteroids 

        13.2.2. PDE4 Inhibitors

        13.2.3. Biologics 

        13.2.4. Skin Barrier Emollients 

        13.2.5. CNI Immunosuppressants

        13.2.6. Others 

    13.3. Market Value Forecast by Distribution Channel, 2017–2027

        13.3.1. Hospital Pharmacies

        13.3.2. Retail Pharmacies 

        13.3.3. Online Pharmacies 

    13.4. Market Value Forecast by Country/Sub-region, 2017–2027

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis 

        13.5.1. By Drug Class

        13.5.2. By Distribution Channel 

        13.5.3. By Country/Sub-region

14. Competitive Landscape

    14.1. Company Profiles

        14.1.1. Mylan N.V.

            14.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.1.1.2. Product Portfolio

            14.1.1.3. SWOT Analysis

            14.1.1.4. Strategic Overview

            14.1.1.5. Financial Overview

        14.1.2. Pfizer, Inc.

            14.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.1.2.2. Product Portfolio

            14.1.2.3. SWOT Analysis

            14.1.2.4. Strategic Overview

            14.1.2.5. Financial Overview

        14.1.3. LEO Pharma A/S

            14.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.1.3.2. Product Portfolio

            14.1.3.3. SWOT Analysis

            14.1.3.4. Strategic Overview

            14.1.3.5. Financial Overview

        14.1.4. Teva Pharmaceutical Industries Ltd

            14.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.1.4.2. Product Portfolio

            14.1.4.3. SWOT Analysis

            14.1.4.4. Strategic Overview

            14.1.4.5. Financial Overview

        14.1.5. Sanofi

            14.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.1.5.2. Product Portfolio

            14.1.5.3. SWOT Analysis

            14.1.5.4. Strategic Overview

            14.1.5.5. Financial Overview

        14.1.6. Novartis AG

            14.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.1.6.2. Product Portfolio

            14.1.6.3. SWOT Analysis

            14.1.6.4. Strategic Overview

            14.1.6.5. Financial Overview